TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma

NCT04103398 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
162
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Sun Yat-sen University